GAMMA Investing LLC Has $175,000 Holdings in Roche Holding AG (OTCMKTS:RHHBY)

GAMMA Investing LLC boosted its holdings in Roche Holding AG (OTCMKTS:RHHBY) by 61.5% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,038 shares of the company’s stock after purchasing an additional 1,919 shares during the quarter. GAMMA Investing LLC’s holdings in Roche were worth $175,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. First Horizon Advisors Inc. lifted its holdings in shares of Roche by 19.8% during the 4th quarter. First Horizon Advisors Inc. now owns 2,066 shares of the company’s stock worth $75,000 after acquiring an additional 342 shares during the period. Bard Financial Services Inc. increased its stake in shares of Roche by 2.0% in the 1st quarter. Bard Financial Services Inc. now owns 20,200 shares of the company’s stock valued at $645,000 after purchasing an additional 400 shares during the last quarter. SVB Wealth LLC raised its holdings in shares of Roche by 2.6% during the 1st quarter. SVB Wealth LLC now owns 16,646 shares of the company’s stock worth $531,000 after buying an additional 426 shares in the last quarter. Confluence Investment Management LLC lifted its position in shares of Roche by 3.7% during the 2nd quarter. Confluence Investment Management LLC now owns 12,922 shares of the company’s stock worth $448,000 after buying an additional 459 shares during the last quarter. Finally, Hancock Whitney Corp grew its position in Roche by 2.4% in the first quarter. Hancock Whitney Corp now owns 28,995 shares of the company’s stock valued at $926,000 after acquiring an additional 678 shares during the last quarter.

Roche Trading Down 3.4 %

Shares of RHHBY traded down $1.37 during trading hours on Tuesday, hitting $39.34. The company’s stock had a trading volume of 964,823 shares, compared to its average volume of 2,197,586. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.35 and a quick ratio of 1.04. The business has a 50 day simple moving average of $35.72 and a two-hundred day simple moving average of $33.41. Roche Holding AG has a 52-week low of $29.20 and a 52-week high of $41.15.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on RHHBY shares. Deutsche Bank Aktiengesellschaft upgraded Roche from a “sell” rating to a “hold” rating in a research report on Friday, May 17th. The Goldman Sachs Group began coverage on Roche in a research note on Thursday, May 30th. They issued a “sell” rating for the company. Two research analysts have rated the stock with a sell rating and five have assigned a hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $40.00.

About Roche

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.